IRIS
AVENALI, MICOL
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.130
AS - Asia 1.607
EU - Europa 1.221
SA - Sud America 322
Continente sconosciuto - Info sul continente non disponibili 112
AF - Africa 84
OC - Oceania 6
Totale 5.482
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.059
CN - Cina 499
SG - Singapore 420
IT - Italia 317
BR - Brasile 244
IE - Irlanda 238
HK - Hong Kong 222
RU - Federazione Russa 185
VN - Vietnam 171
DE - Germania 136
BD - Bangladesh 96
FR - Francia 90
FI - Finlandia 72
IN - India 53
ZA - Sudafrica 53
GB - Regno Unito 49
CA - Canada 31
NL - Olanda 25
AR - Argentina 22
MX - Messico 22
JP - Giappone 20
ID - Indonesia 18
CO - Colombia 17
PL - Polonia 17
IQ - Iraq 15
PK - Pakistan 12
SE - Svezia 12
CZ - Repubblica Ceca 11
ES - Italia 10
MA - Marocco 10
TR - Turchia 10
UA - Ucraina 10
VE - Venezuela 9
AT - Austria 8
EC - Ecuador 8
JO - Giordania 8
PH - Filippine 8
BE - Belgio 7
MY - Malesia 7
AL - Albania 6
CL - Cile 6
KG - Kirghizistan 6
PY - Paraguay 6
UZ - Uzbekistan 6
AU - Australia 5
KR - Corea 5
MO - Macao, regione amministrativa speciale della Cina 5
CH - Svizzera 4
EG - Egitto 4
KE - Kenya 4
SA - Arabia Saudita 4
UY - Uruguay 4
BO - Bolivia 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
GT - Guatemala 3
KZ - Kazakistan 3
LT - Lituania 3
PE - Perù 3
RO - Romania 3
RS - Serbia 3
SI - Slovenia 3
TN - Tunisia 3
AZ - Azerbaigian 2
DK - Danimarca 2
DZ - Algeria 2
GR - Grecia 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MQ - Martinica 2
NP - Nepal 2
SN - Senegal 2
SV - El Salvador 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BW - Botswana 1
CW - ???statistics.table.value.countryCode.CW??? 1
DJ - Gibuti 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
LC - Santa Lucia 1
MD - Moldavia 1
MM - Myanmar 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
QA - Qatar 1
Totale 5.367
Salva come PNG Salva come JPEG
Città #
San Jose 291
Dublin 227
Singapore 225
Hong Kong 219
Chandler 214
Dallas 179
Ashburn 175
Beijing 130
Council Bluffs 97
Boardman 81
Los Angeles 77
Milan 60
Ho Chi Minh City 57
Lauterbourg 52
New York 52
Helsinki 48
Johannesburg 47
Santa Clara 47
Rome 46
Munich 41
Hanoi 39
Shanghai 38
Moscow 36
Princeton 34
Lawrence 32
Nanjing 30
Medford 29
Redondo Beach 29
Wilmington 29
São Paulo 27
Columbus 25
Buffalo 24
Orem 24
Frankfurt am Main 20
Turku 18
Hebei 17
Tokyo 17
Warsaw 17
The Dalles 16
Nanchang 15
Nuremberg 15
Chennai 14
Jacksonville 14
Amsterdam 13
Brooklyn 13
Hangzhou 13
London 12
Naples 12
Falkenstein 11
Florence 11
Pavia 11
Seattle 11
Shenyang 11
Düsseldorf 10
Fairfield 10
Figino 10
Haiphong 10
Mexico City 10
Phoenix 10
Rio de Janeiro 10
Toronto 10
Changsha 9
Chicago 9
Houston 9
Montreal 9
Amman 8
Norwalk 8
Stockholm 8
Tianjin 8
Ann Arbor 7
Belo Horizonte 7
Boston 7
Brno 7
Cagliari 7
Da Nang 7
Guangzhou 7
Menlo Park 7
Turin 7
Baghdad 6
Bishkek 6
Biên Hòa 6
Dhaka 6
Les Paris 6
Medellín 6
Poplar 6
Pune 6
Tashkent 6
Bakersfield 5
Bogotá 5
Brussels 5
Denver 5
Elk Grove Village 5
Falls Church 5
Fortaleza 5
Frascati 5
Hyderabad 5
Jakarta 5
Jiaxing 5
Macao 5
Mumbai 5
Totale 3.372
Salva come PNG Salva come JPEG
Nome #
CLINICAL AND BIOCHEMICAL SIGNATURES OF GBA-RELATED PARKINSON DISEASE 177
Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy 151
Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism 151
A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value 133
Consensus on the treatment of dysphagia in Parkinson's disease 131
Body Weight Support Combined With Treadmill in the Rehabilitation of Parkinsonian Gait: A Review of Literature and New Data From a Controlled Study 129
Pain processing in atypical Parkinsonisms and Parkinson disease: A comparative neurophysiological study 128
What is the role of the placebo effect for pain relief in neurorehabilitation? Clinical implications from the Italian consensus conference on pain in neurorehabilitation 124
Time for a consensus conference on pain in neurorehabilitation 122
KCTD17-related myoclonus-dystonia syndrome: clinical and electrophysiological findings of a patient with atypical late onset 122
GBA-Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort 115
Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: A placebo controlled study. 113
Extracellular Vesicles Derived From Plasma of Patients With Neurodegenerative Disease Have Common Transcriptomic Profiling 113
Botulinum toxin for chronic migraine: Clinical trials and technical aspects 112
Reproducibility and reaction time of swallowing as markers of dysphagia in parkinsonian syndromes 112
Blood D-serine levels correlate with aging and dopaminergic treatment in Parkinson's disease 110
Different miRNA profiles in plasma derived small and large extracellular vesicles of neurodegenerative disease patients. 110
Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project 109
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol 107
Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations 106
Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy 103
Outcomes of a computer-based cognitive training (CoRe) in early phases of cognitive decline: a data-driven cluster analysis 102
The Effects of Intensive Neurorehabilitation on Sequence Effect in Parkinson's Disease Patients With and Without Freezing of Gait 102
Clinical and Electrophysiological Outcome Measures of Patients With Post-Infectious Neurological Syndromes Related to COVID-19 Treated With Intensive Neurorehabilitation 96
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease 92
Gba mutations influence the release and pathological effects of small extracellular vesicles from fibroblasts of patients with parkinson’s disease 92
The role of stroke-induced immunosuppression as a predictor of functional outcome in the neurorehabilitation setting 89
Non-Invasive Neuromodulation in the Rehabilitation of Pisa Syndrome in Parkinson's Disease: A Randomized Controlled Trial 85
The exosomal/total α-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients 84
The role of stroke-induced immunosuppression as a predictor of functional outcome in the neurorehabilitation setting 82
Harmonic ratio is the most responsive trunk-acceleration derived gait index to rehabilitation in people with Parkinson’s disease at moderate disease stages 80
A narrative review on the role and main findings of the Videofluoroscopic Study of Swallowing in Parkison's disease 79
Are patients with GBA-Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort 74
Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectivology: Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation 74
Apomorphine Subcutaneous Infusion Likely Induced Acute Thrombocytopenia in a Patient with Parkinson's Disease and Motor Fluctuations 71
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort 71
Serum dysregulation of serine and glycine metabolism as predictive biomarker for cognitive decline in frail elderly subjects 69
Exploring the neural and behavioral correlates of cognitive telerehabilitation in mild cognitive impairment with three distinct approaches 66
Bilateral Dentate Nuclei Hyperintensities and Response to 4-Aminopyridine in a Patient With Childhood-Onset GAA- FGF14 -Related Ataxia 66
Impaired Mitochondrial Respiration in REM-Sleep Behavior Disorder: A Biomarker of Parkinson's Disease? 65
From DYMUS to DYPARK: Validation of a Screening Questionnaire for Dysphagia in Parkinson’s Disease 65
Pearls & Oy-sters: Marionette Walk in Parkinson Disease 64
Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) 62
Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: A 6-year longitudinal study 60
Evaluation of the efficacy of physical therapy on cognitive decline at 6-month follow-up in Parkinson disease patients with mild cognitive impairment: a randomized controlled trial 58
Psychological treatments and psychotherapies in the neurorehabilitation of pain: Evidences and recommendations from the italian consensus conference on pain in neurorehabilitation 57
Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells 56
The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease 56
CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variants 55
Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study 54
Outcomes of a computer-based cognitive training (CoRe) in early phases of cognitive decline: a data-driven cluster analysis 53
Functional Study of SNCA p.V15A Variant: Further Linking α-Synuclein and Glucocerebrosidase 50
Proprioceptive Focal Stimulation (Equistasi®) May Improve the Quality of Gait in Middle-Moderate Parkinson's Disease Patients. Double-Blind, Double-Dummy, Randomized, Crossover, Italian Multicentric Study 50
Parkinson disease following COVID-19: Report of six cases 49
Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A six-month follow-up of the COMOESTAS Project 49
Team Science Approaches to Unravel Monogenic Parkinson's Disease on a Global Scale 48
Reply to: “Increased alpha-Synuclein Level in CD45+ Blood Cells in Asymptomatic Carriers of GBA Mutations” 48
LC-MS/MS-Based Determination of Ambroxol in Human Plasma and Cerebrospinal Fluid: Validation and Applicability in a Phase II Study on GBA-Associated Parkinson’s Disease Patients 45
Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a GBA1 Pathogenic Variant 40
Plasma extracellular vesicles and phosphorylated tau 181 as early biomarkers of cognitive impairment in Alzheimer’s dementia 38
Pain in focal dystonias - A focused review to address an important component of the disease 37
Genetic and Epidemiological Insights into RAB32-Linked Parkinson's Disease 33
Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach 32
null 30
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study 29
RAB32 mutation in Parkinson's disease [2] 26
1H-NMR-based metabolomics identifies disrupted betaine metabolism as distinct serum signature of pre-frailty 13
Clustering Algorithm Reveals Dopamine-Motor Mismatch in Cognitively Preserved Parkinson's Disease 12
Microbiome signature of Parkinson's disease in healthy and genetically at-risk individuals 11
Unraveling the role of GBA1 genotype in axial signs response to subthalamic deep brain stimulation 9
The interplay between GBA1 status and age of onset on cognitive, motor and non-motor outcomes in Parkinson's disease: multicenter cross-sectional study 9
Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review 8
Initiating foslevodopa infusion in Parkinson disease: a pragmatic study 8
The treatment of axial and foot dystonia 6
RAB32-Linked Parkinson's Disease: Deep Phenotyping, MDSGene Literature Review, and Application of SynNeurGe Criteria 5
LONG-NEXT: A new accurate and efficient NGS-based method for GBA1 analysis in Parkinson disease 5
Asymmetric Parietal Cortical Atrophy in a Patient with RAB39B-Associated Parkinsonism 5
Severe GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials 5
Domain-driven verbal and non-verbal dissociations in cognition and social cognition in Parkinson’s disease 5
Titration Dynamics and Early Treatment Burden in Advanced Parkinson's Disease: A Multicenter Comparison of CSFLI and LCIG Infusion Therapies 4
Male sex accelerates cognitive decline in GBA1 Parkinson’s disease 4
Combined assessment of blood glucocerebrosidase activity and α-synuclein levels in GBA1 mutation carriers: A novel potential biomarker 4
Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation-Wide, Multicenter, Longitudinal, “Real-World” Study. The EPIC Study 3
Independent serum metabolomics approaches identify disrupted glutamic acid and serine metabolism in Parkinson’s disease patients 3
Loss of serotonergic function in carriers of PRKN mutations: a [11C]DASB PET study 2
Totale 5.482
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.766
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.766
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022184 0 1 1 16 9 13 3 13 11 1 20 96
2022/2023576 59 54 5 69 33 46 1 22 261 3 15 8
2023/2024360 37 48 8 22 11 70 29 24 2 11 50 48
2024/20251.144 39 60 21 21 44 116 128 63 260 61 124 207
2025/20262.687 196 193 279 267 288 94 442 139 273 208 191 117
2026/2027285 104 181 0 0 0 0 0 0 0 0 0 0
Totale 5.482